Squarepoint
DMRA

Squarepoint’s Damora Therapeutics DMRA Stock Holding History

Squarepoint’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303K Sell
11,668
-11,790
-50% -$285K ﹤0.01% 3795
2026
Q1 		$608K Buy
+23,458
New +$603K ﹤0.01% 3179
2025
Q2 		– Sell
-12,984
Closed -$40.3K – 4692
2025
Q1 		$40.3K Buy
12,984
+283
+2% +$1.33K ﹤0.01% 4377
2024
Q4 		$59.1K Buy
+12,701
New +$83.1K ﹤0.01% 4812

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Squarepoint's DMRA Position: Q2 2026 in Review

Squarepoint reduced its Damora Therapeutics (DMRA) stake by 50% in Q2 2026, selling an estimated $285K and leaving 11,668 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #3795.

Squarepoint first reported a position in DMRA in Q4 2024 and has held it in 4 quarters since. The position peaked at $608K in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Squarepoint held 11,668 shares of Damora Therapeutics worth $303K as of Q2 2026.
  • Squarepoint sold 11,790 Damora Therapeutics shares in Q2 2026, an estimated $285K.
  • Damora Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3795 holding.
  • Squarepoint first reported a position in Damora Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Squarepoint's Damora Therapeutics position peaked at $608K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.